LUPRON TREATMENT OF PROGRESSIVE PRECOCIOUS PUBERTY

Lupron 治疗进行性性早熟

• 批准号: 6113150
• 负责人: JOHN S. PARKS
• 金额: $ 3.88万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113150
• 关键词: adolescence (12-20); body height; bone density; child (0-11); clinical research; drug administration rate /duration; endocrine disorder chemotherapy; hormone therapy; human puberty; human subject; human therapy evaluation; leuprolide; pediatric pharmacology; precocious puberty; reproductive system disorder chemotherapy; slow release drug

This study assesses the effectiveness of Lupron (a GnRH agonist) to inhibit progression of central precocious puberty. Monthly injections of a depot preparation have replaced daily injections of a rapidly-absorbed preparation. Outcome measures include skeletal density, pubertal staging, statural growth, and adult height attainment. Eight patients have completed the study, 2 are in therapy and 1 is in followup.

本研究评估了Lupron（一种GnRH激动剂）抑制中枢性早熟进展的有效性。 长效制剂的每月注射已经取代了快速吸收制剂的每日注射。 结果测量包括骨骼密度，青春期分期，身高增长和成人身高的获得。 8例患者已完成研究，2例正在治疗，1例正在随访。